Roivant Sciences Ltd. (ROIV)

Market Cap	9.55B
Revenue (ttm)	23.23M
Net Income (ttm)	-490.63M
Shares Out	682.88M
EPS (ttm)	-0.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	334,526
Open	13.95
Previous Close	13.95
Day's Range	13.93 - 14.19
52-Week Range	8.73 - 14.48
Beta	1.15
Analysts	Strong Buy
Price Target	15.50 (+10.79%)
Earnings Date	Nov 11, 2025

About ROIV

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monocl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 750
• Stock Exchange: NASDAQ
• Ticker Symbol: ROIV
• Website: https://roivant.com

Analyst Summary

According to 4 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 10.79% from the latest price.

Price Target

$15.5

(10.79% upside)

Analyst Consensus: Strong Buy